サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：副甲状腺機能低下症治療の世界市場規模調査：製品別（副甲状腺ホルモン、ビタミンDアナログ、カルシウムサプリメント）、投与方法別（経口、非経口）、地域別予測：2021年～2027年
市場調査レポート
商品コード
1045646

副甲状腺機能低下症治療の世界市場規模調査：製品別（副甲状腺ホルモン、ビタミンDアナログ、カルシウムサプリメント）、投与方法別（経口、非経口）、地域別予測：2021年～2027年

Global Hypoparathyroidism Treatment Market Size study, by Product (Parathyroid Hormone, Vitamin D Analogue, Calcium Supplements), by Administration (Oral, Parenteral) and Regional Forecasts 2021-2027
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日
AI翻訳ツール 提供対象
ご購入後の翻訳ツール提供について

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=128.87円
副甲状腺機能低下症治療の世界市場規模調査：製品別（副甲状腺ホルモン、ビタミンDアナログ、カルシウムサプリメント）、投与方法別（経口、非経口）、地域別予測：2021年～2027年
出版日: 2022年01月08日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の副甲状腺機能低下症治療の市場規模は、2021年～2027年の予測期間に健全な成長率で拡大すると予測されています。

副甲状腺機能低下症治療市場は、胸部手術の増加や癌の発生率の上昇、新薬の開発や政府の支援により、予測期間中に採用が進むとみられています。また、技術的に進歩した治療法の導入が進んでいることから、副甲状腺機能低下症治療の導入と需要が進み、予測期間中の市場の成長を高めると考えられます。しかし、臨床承認に時間を要することが、2021年～2027年の予測期間における市場の成長を妨げています。

当レポートでは、世界の副甲状腺機能低下症治療市場について調査し、市場の概要とともに、製品別、投与方法別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 世界の副甲状腺機能低下症治療市場の定義と範囲

第3章 世界の副甲状腺機能低下症治療市場力学

  • 副甲状腺機能低下症治療市場の影響分析（2019年～2027年）

第4章 世界の副甲状腺機能低下症治療市場業界分析

  • ポーターの5フォースモデル
  • PEST分析
  • 投資採用モデル
  • アナリストの推奨事項と結論
  • 主な投資の機会
  • 主な勝利戦略

第5章 リスク評価：COVID-19の影響

    • 業界に対するCOVID-19の全体的な影響評価
    • COVID-19以前およびCOVID-19以後の市場シナリオ

第6章 世界の副甲状腺機能低下症治療市場、製品別

  • 市場スナップショット
  • 世界の副甲状腺機能低下症治療市場、製品別：実績-潜在性分析
  • 世界の副甲状腺機能低下症治療市場の見積と予測、製品別：2018年～2027年（10億米ドル）
  • 副甲状腺機能低下症治療市場、サブセグメント分析
    • 副甲状腺ホルモン
    • ビタミンDアナログ
    • カルシウムサプリメント

第7章 世界の副甲状腺機能低下症治療市場、投与方法別

  • 市場スナップショット
  • 世界の副甲状腺機能低下症治療市場、投与方法別：実績-潜在性分析
  • 世界の副甲状腺機能低下症治療市場の見積と予測、投与方法別：2018年～2027年（10億米ドル）
  • 副甲状腺機能低下症治療市場、サブセグメント分析
    • 経口
    • 非経口

第8章 世界の副甲状腺機能低下症治療市場、地域分析

  • 地域市場のスナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州のスナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他
  • アジア太平洋のスナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他
  • ラテンアメリカのスナップショット
    • ブラジル
    • メキシコ
  • その他の地域

第9章 競合情報

  • 主な市場戦略
  • 企業プロファイル
    • Shire NPS Pharmaceuticals Inc.
    • Takeda Pharmaceutical Company Limited.
    • Entera Bio Ltd.
    • Amgen Inc.
    • Ascendis Pharma A/S
    • F. Hoffmann-La Roche Ltd
    • ProLynx, Inc.
    • Extend Biosciences, Inc.
    • BionPharma Inc.
    • F Hoffmann-La Roche Ltd.

第10章 調査プロセス

図表

LIST OF TABLES

  • TABLE 1. Global Hypoparathyroidism Treatment market, report scope
  • TABLE 2. Global Hypoparathyroidism Treatment market estimates & forecasts by Region 2018-2027 (USD Billion)
  • TABLE 3. Global Hypoparathyroidism Treatment market estimates & forecasts by Product 2018-2027 (USD Billion)
  • TABLE 4. Global Hypoparathyroidism Treatment market estimates & forecasts by Administration 2018-2027 (USD Billion)
  • TABLE 5. Global Hypoparathyroidism Treatment market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 6. Global Hypoparathyroidism Treatment market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 7. Global Hypoparathyroidism Treatment market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 8. Global Hypoparathyroidism Treatment market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 9. Global Hypoparathyroidism Treatment market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 10. Global Hypoparathyroidism Treatment market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 11. Global Hypoparathyroidism Treatment market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 12. Global Hypoparathyroidism Treatment market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 13. Global Hypoparathyroidism Treatment market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 14. Global Hypoparathyroidism Treatment market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 15. U.S. Hypoparathyroidism Treatment market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 16. U.S. Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 17. U.S. Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 18. Canada Hypoparathyroidism Treatment market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 19. Canada Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 20. Canada Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 21. UK Hypoparathyroidism Treatment market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 22. UK Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 23. UK Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 24. Germany Hypoparathyroidism Treatment market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 25. Germany Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 26. Germany Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 27. RoE Hypoparathyroidism Treatment market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 28. RoE Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 29. RoE Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 30. China Hypoparathyroidism Treatment market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 31. China Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 32. China Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 33. India Hypoparathyroidism Treatment market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 34. India Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 35. India Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 36. Japan Hypoparathyroidism Treatment market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 37. Japan Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 38. Japan Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 39. RoAPAC Hypoparathyroidism Treatment market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 40. RoAPAC Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 41. RoAPAC Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 42. Brazil Hypoparathyroidism Treatment market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 43. Brazil Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 44. Brazil Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 45. Mexico Hypoparathyroidism Treatment market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 46. Mexico Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 47. Mexico Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 48. RoLA Hypoparathyroidism Treatment market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 49. RoLA Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 50. RoLA Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 51. Row Hypoparathyroidism Treatment market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 52. Row Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 53. Row Hypoparathyroidism Treatment market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 54. List of secondary sources, used in the study of global Hypoparathyroidism Treatment market
  • TABLE 55. List of primary sources, used in the study of global Hypoparathyroidism Treatment market
  • TABLE 56. Years considered for the study
  • TABLE 57. Exchange rates considered

LIST OF FIGURES

List of figures

  • FIG 1. Global Hypoparathyroidism Treatment market, research methodology
  • FIG 2. Global Hypoparathyroidism Treatment market, market estimation techniques
  • FIG 3. Global market size estimates & forecast methods
  • FIG 4. Global Hypoparathyroidism Treatment market, key trends 2020
  • FIG 5. Global Hypoparathyroidism Treatment market, growth prospects 2021-2027
  • FIG 6. Global Hypoparathyroidism Treatment market, porters 5 force model
  • FIG 7. Global Hypoparathyroidism Treatment market, pest analysis
  • FIG 8. Global Hypoparathyroidism Treatment market, value chain analysis
  • FIG 9. Global Hypoparathyroidism Treatment market by segment, 2018 & 2027 (USD Billion)
  • FIG 10. Global Hypoparathyroidism Treatment market by segment, 2018 & 2027 (USD Billion)
  • FIG 11. Global Hypoparathyroidism Treatment market by segment, 2018 & 2027 (USD Billion)
  • FIG 12. Global Hypoparathyroidism Treatment market by segment, 2018 & 2027 (USD Billion)
  • FIG 13. Global Hypoparathyroidism Treatment market by segment, 2018 & 2027 (USD Billion)
  • FIG 14. Global Hypoparathyroidism Treatment market, regional snapshot 2018 & 2027
  • FIG 15. North America Hypoparathyroidism Treatment market 2018 & 2027 (USD Billion)
  • FIG 16. Europe Hypoparathyroidism Treatment market 2018 & 2027 (USD Billion)
  • FIG 17. Asia pacific Hypoparathyroidism Treatment market 2018 & 2027 (USD Billion)
  • FIG 18. Latin America Hypoparathyroidism Treatment market 2018 & 2027 (USD Billion)
  • FIG 19. Global Hypoparathyroidism Treatment market, company market share analysis (2020)
目次

Global Hypoparathyroidism Treatment Market is valued at approximately USD XX billion in 2020 and is anticipated to grow with a healthy growth rate of more than XX % over the forecast period 2021-2027. Hypoparathyroidism Treatment is a treatment in which a low level of parathyroid hormone is produced by hypoparathyroidism. Parathyroid hormone maintains and regulates the balance between calcium and phosphorus. Increasing number of thoracic surgeries and incidence of cancer, new drug development and government support have led to the adoption of Hypoparathyroidism Treatment across the forecast period. For Instance: as per the National Cancer Institute in 2020, an estimated 1,806,590 new cases of cancer will be diagnosed in the United States and 606,520 people will die from the disease. Also, with the increasing adoption of technologically advanced treatment, the adoption & demand for Hypoparathyroidism Treatment is likely to increase the market growth during the forecast period. However, lengthy clinical approval cycles impede the growth of the market over the forecast period of 2021-2027.

The key regions considered for the global Hypoparathyroidism Treatment market study include Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world in terms of market share owing to increasing thyroid-related diseases and increasing initiatives by pharmaceutical organizations to generate novel formulations. Whereas, Asia-Pacific is also anticipated to exhibit the highest growth rate over the forecast period 2021-2027. Factors such as the presence of generic manufacturers would create lucrative growth prospects for the Hypoparathyroidism Treatment market across Asia-Pacific region.

Major market players included in this report are:

Shire NPS Pharmaceuticals Inc.

Takeda Pharmaceutical Company Limited.

Entera Bio Ltd.

Amgen Inc.

Ascendis Pharma A/S

F. Hoffmann-La Roche Ltd

ProLynx, Inc.

Extend Biosciences, Inc.

BionPharma Inc.

F Hoffmann-La Roche Ltd.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

Parathyroid Hormone

Vitamin D Analogue

Calcium Supplements

By Administration:

Oral

Parenteral

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019

Base year - 2020

Forecast period - 2021 to 2027

Target Audience of the Global Hypoparathyroidism Treatment Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
    • 1.2.1. Global Hypoparathyroidism Treatment Market, by Region, 2019-2027 (USD Billion)
    • 1.2.2. Global Hypoparathyroidism Treatment Market, by Product, 2019-2027 (USD Billion)
    • 1.2.3. Global Hypoparathyroidism Treatment Market, by Administration, 2019-2027 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Hypoparathyroidism Treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Hypoparathyroidism Treatment Market Dynamics

  • 3.1. Hypoparathyroidism Treatment Market Impact Analysis (2019-2027)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing number of thoracic surgeries and incidence of cancer
      • 3.1.1.2. New drug development and government support
    • 3.1.2. Market Challenges
      • 3.1.2.1. Lengthy clinical approval cycles
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increasing adoption of technologically advanced treatment

Chapter 4. Global Hypoparathyroidism Treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2027)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion
  • 4.5. Top investment opportunity
  • 4.6. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

    • 5.1.1. Assessment of the overall impact of COVID-19 on the industry
    • 5.1.2. Pre COVID-19 and post COVID-19 market scenario

Chapter 6. Global Hypoparathyroidism Treatment Market, by Product

  • 6.1. Market Snapshot
  • 6.2. Global Hypoparathyroidism Treatment Market by Product, Performance - Potential Analysis
  • 6.3. Global Hypoparathyroidism Treatment Market Estimates & Forecasts by Product, 2018-2027 (USD Billion)
  • 6.4. Hypoparathyroidism Treatment Market, Sub Segment Analysis
    • 6.4.1. Parathyroid Hormone
    • 6.4.2. Vitamin D Analogue
    • 6.4.3. Calcium Supplements

Chapter 7. Global Hypoparathyroidism Treatment Market, by Administration

  • 7.1. Market Snapshot
  • 7.2. Global Hypoparathyroidism Treatment Market by Administration, Performance - Potential Analysis
  • 7.3. Global Hypoparathyroidism Treatment Market Estimates & Forecasts by Administration, 2018-2027 (USD Billion)
  • 7.4. Hypoparathyroidism Treatment Market, Sub Segment Analysis
    • 7.4.1. Oral
    • 7.4.2. Parenteral

Chapter 8. Global Hypoparathyroidism Treatment Market, Regional Analysis

  • 8.1. Hypoparathyroidism Treatment Market, Regional Market Snapshot
  • 8.2. North America Hypoparathyroidism Treatment Market
    • 8.2.1. U.S. Hypoparathyroidism Treatment Market
      • 8.2.1.1. Product breakdown estimates & forecasts, 2018-2027
      • 8.2.1.2. Administration breakdown estimates & forecasts, 2018-2027
    • 8.2.2. Canada Hypoparathyroidism Treatment Market
  • 8.3. Europe Hypoparathyroidism Treatment Market Snapshot
    • 8.3.1. U.K. Hypoparathyroidism Treatment Market
    • 8.3.2. Germany Hypoparathyroidism Treatment Market
    • 8.3.3. France Hypoparathyroidism Treatment Market
    • 8.3.4. Spain Hypoparathyroidism Treatment Market
    • 8.3.5. Italy Hypoparathyroidism Treatment Market
    • 8.3.6. Rest of Europe Hypoparathyroidism Treatment Market
  • 8.4. Asia-Pacific Hypoparathyroidism Treatment Market Snapshot
    • 8.4.1. China Hypoparathyroidism Treatment Market
    • 8.4.2. India Hypoparathyroidism Treatment Market
    • 8.4.3. Japan Hypoparathyroidism Treatment Market
    • 8.4.4. Australia Hypoparathyroidism Treatment Market
    • 8.4.5. South Korea Hypoparathyroidism Treatment Market
    • 8.4.6. Rest of Asia Pacific Hypoparathyroidism Treatment Market
  • 8.5. Latin America Hypoparathyroidism Treatment Market Snapshot
    • 8.5.1. Brazil Hypoparathyroidism Treatment Market
    • 8.5.2. Mexico Hypoparathyroidism Treatment Market
  • 8.6. Rest of The World Hypoparathyroidism Treatment Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. Shire NPS Pharmaceuticals Inc.
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Takeda Pharmaceutical Company Limited.
    • 9.2.3. Entera Bio Ltd.
    • 9.2.4. Amgen Inc.
    • 9.2.5. Ascendis Pharma A/S
    • 9.2.6. F. Hoffmann-La Roche Ltd
    • 9.2.7. ProLynx, Inc.
    • 9.2.8. Extend Biosciences, Inc.
    • 9.2.9. BionPharma Inc.
    • 9.2.10. F Hoffmann-La Roche Ltd.,

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption